The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae652 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Victoria R van Trigt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Albinusdreef 2, 2333 ZA …. Hauptthemen laut MEDLINE: Prolactinoma, Pituitary Neoplasms, Neurosurgical Procedures. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate patients with prolactinoma treated surgically in a time when elective prolactinoma surgery became routine in our center, using a comprehensive outcome set, focusing on preoperative assessments, surgical outcomes, and health-related quality of life (HR-QoL).
Methods
Cohort of consecutive patients with prolactinoma undergoing surgery between January 2021 and August 2023. Clinical data were collected during multidisciplinary team meetings/from medical records at distinct timepoints: (1) presurgery, (2) 2 weeks postsurgery, (3) 6 months postsurgery, and (4) follow-up (median, 15.0 [10.0-24.8 months]). HR-QoL was measured using the Leiden Bothers and Needs Pituitary questionnaire. Data were described for all patients, and patients undergoing elective total resection, with additional subgroups of (1) patients undergoing a high-probability first total resection and (2) reoperations aiming for total resection.
Results
One hundred surgically treated patients with prolactinoma were included (72 female). Dopamine agonist intolerance was the most frequent indication (n = 68). The surgical goal (debulking/total resection) was achieved in 90% of patients. Long-term complications occurred in 4% of patients. Seventy-eight patients underwent an elective total resection, achieving remission in 91%. The subsets of preoperatively estimated high-probability-first total resections (n = 52) and reoperations (n = 9) achieved remission in 92% and 89%, respectively. Leiden Bothers and Needs Pituitary Total Bothers and Total Needs scores improved significantly after surgery (P < .001, Δ-3.4 [interquartile range, −14.4 to −0.9] and P = .006, Δ-1.8 [interquartile range, −11.9 to 1.3]), respectively.
Conclusion
High remission rates were achieved, improving HR-QoL, demonstrating (repeat) prolactinoma surgery is effective in an experienced pituitary center, as highlighted in the most recent guideline (2023).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
- Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
- Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
- Department of Neurosurgery, Leiden University Medical Center, University Neurosurgical Center Holland, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
ORCID-Profile: Victoria R van Trigt, Iris C M Pelsma, Ingrid M Zandbergen, Maaia M Jentus, Mark C Kruit, Olaf M Dekkers, Wouter R van Furth, Marco J T Verstegen, Nienke R Biermasz
Zitieren
APA
van Trigt, V. R., Bakker, L. E. H., Pelsma, I. C. M., Zandbergen, I. M., Jentus, M. M., Kruit, M. C., Dekkers, O. M., van Furth, W. R., Verstegen, M. J. T., Biermasz, N. R., & Dutch Prolactinoma Study Group (2025). The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae652
Vancouver
van Trigt VR, Bakker LEH, Pelsma ICM, Zandbergen IM, Jentus MM, Kruit MC, et al. The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae652
BibTeX
@article{vanTrigt2025,
author = {van Trigt, Victoria R and Bakker, Leontine E H and Pelsma, Iris C M and Zandbergen, Ingrid M and Jentus, Maaia M and Kruit, Mark C and Dekkers, Olaf M and van Furth, Wouter R and Verstegen, Marco J T and Biermasz, Nienke R and Dutch Prolactinoma Study Group, Dutch Prolactinoma Study Group},
title = {The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae652}
}
EUVIMED